Intercept Pharmaceuticals Shares Outstanding 2011-2021 | ICPT

Intercept Pharmaceuticals shares outstanding from 2011 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Intercept Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2020 33
2019 32
2018 28
2017 25
2016 25
2015 24
2014 21
2013 18
2012 6
2011 3
2010 3
Intercept Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 33
2021-03-31 33
2020-12-31 33
2020-09-30 33
2020-06-30 33
2020-03-31 33
2019-12-31 32
2019-09-30 33
2019-06-30 31
2019-03-31 30
2018-12-31 28
2018-09-30 30
2018-06-30 29
2018-03-31 25
2017-12-31 25
2017-09-30 25
2017-06-30 25
2017-03-31 25
2016-12-31 25
2016-09-30 25
2016-06-30 25
2016-03-31 24
2015-12-31 24
2015-09-30 24
2015-06-30 24
2015-03-31 22
2014-12-31 21
2014-09-30 21
2014-06-30 22
2014-03-31 20
2013-12-31 18
2013-09-30 19
2013-06-30 17
2013-03-31 17
2012-12-31 15
2012-09-30 3
2012-06-30 3
2012-03-31 3
2011-12-31
2011-09-30 3
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.569B $0.313B
Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76